Stephan Stilgenbauer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5664937/publications.pdf

Version: 2024-02-01

616	39,417	3334	3323
papers	citations	91 h-index	184 g-index

639	639	639	22992
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2000, 343, 1910-1916.	27.0	2,967
2	Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2014, 370, 997-1007.	27.0	1,535
3	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. New England Journal of Medicine, 2013, 369, 507-516.	27.0	1,449
4	Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. New England Journal of Medicine, 2014, 370, 1101-1110.	27.0	1,284
5	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 2018, 131, 2745-2760.	1.4	1,069
6	Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib. New England Journal of Medicine, 2014, 370, 2286-2294.	27.0	1,042
7	Mutations driving CLL and their evolution in progression and relapse. Nature, 2015, 526, 525-530.	27.8	868
8	V H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood, 2002, 100, 1410-1416.	1.4	690
9	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncology, The, 2016, 17, 768-778.	10.7	676
10	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. New England Journal of Medicine, 2019, 380, 2225-2236.	27.0	599
11	Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood, 2016, 127, 208-215.	1.4	571
12	Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2010, 28, 1749-1755.	1.6	541
13	First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncology, The, 2016, 17, 928-942.	10.7	529
14	Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood, 2005, 107, 885-891.	1.4	524
15	TP53 Mutation and Survival in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2010, 28, 4473-4479.	1.6	523
16	From pathogenesis to treatment of chronic lymphocytic leukaemia. Nature Reviews Cancer, 2010, 10, 37-50.	28.4	503
17	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology,the, 2016, 3, e217-e227.	4.6	442
18	Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood, 2014, 123, 3247-3254.	1.4	428

#	Article	IF	Citations
19	Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial. Journal of Clinical Oncology, 2012, 30, 980-988.	1.6	397
20	Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology, 2012, 30, 3209-3216.	1.6	388
21	11q Deletions Identify a New Subset of B-Cell Chronic Lymphocytic Leukemia Characterized by Extensive Nodal Involvement and Inferior Prognosis. Blood, 1997, 89, 2516-2522.	1.4	363
22	Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood, 2008, 112, 3322-3329.	1.4	348
23	Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology, 2011, 29, 3559-3566.	1.6	342
24	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet, The, 2016, 388, 565-575.	13.7	328
25	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncology, The, 2016, 17, 1409-1418.	10.7	290
26	Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. Journal of Clinical Oncology, 2016, 34, 1386-1394.	1.6	276
27	Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood, 2010, 116, 2438-2447.	1.4	273
28	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of Clinical Oncology, 2021, 39, 3441-3452.	1.6	266
29	The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood, 2018, 132, 2446-2455.	1.4	261
30	miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood, 2009, 113, 3801-3808.	1.4	258
31	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematology,the, 2017, 4, e510-e523.	4.6	258
32	Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology, 2009, 27, 3994-4001.	1.6	257
33	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. Journal of Clinical Oncology, 2018, 36, 1973-1980.	1.6	257
34	DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nature Genetics, 2016, 48, 253-264.	21.4	254
35	Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood, 2009, 114, 2589-2597.	1.4	253
36	Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis. Cancer Cell, 2012, 22, 167-179.	16.8	251

#	Article	IF	Citations
37	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood, 2014, 124, 49-62.	1.4	244
38	Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nature Medicine, 1997, 3, 1155-1159.	30.7	243
39	Tumor-derived exosomes modulate PD-L1 expression in monocytes. Science Immunology, 2017, 2, .	11.9	236
40	Somatic ATM Mutations Indicate a Pathogenic Role of ATM in B-Cell Chronic Lymphocytic Leukemia. Blood, 1999, 94, 748-753.	1.4	233
41	Postibrutinib outcomes in patients with mantle cell lymphoma. Blood, 2016, 127, 1559-1563.	1.4	228
42	Cellular origin and pathophysiology of chronic lymphocytic leukemia. Journal of Experimental Medicine, 2012, 209, 2183-2198.	8.5	227
43	Automated array-based genomic profiling in chronic lymphocytic leukemia: Development of a clinical tool and discovery of recurrent genomic alterations. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1039-1044.	7.1	221
44	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncology, The, 2017, 18, 297-311.	10.7	219
45	Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. Journal of Molecular Medicine, 1999, 77, 266-281.	3.9	215
46	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2020, 21, 1188-1200.	10.7	208
47	V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood, 2002, 100, 1410-6.	1.4	206
48	Microarray Gene Expression Profiling of B-Cell Chronic Lymphocytic Leukemia Subgroups Defined by Genomic Aberrations and VH Mutation Status. Journal of Clinical Oncology, 2004, 22, 3937-3949.	1.6	200
49	Campath-1Hâ€“Induced Complete Remission of Chronic Lymphocytic Leukemia despitep53Gene Mutation and Resistance to Chemotherapy. New England Journal of Medicine, 2002, 347, 452-453.	27.0	195
50	Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica, 2007, 92, 1242-1245.	3.5	195
51	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Annals of Oncology, 2013, 24, 561-576.	1.2	193
52	miRNA-130a Targets ATG2B and DICER1 to Inhibit Autophagy and Trigger Killing of Chronic Lymphocytic Leukemia Cells. Cancer Research, 2012, 72, 1763-1772.	0.9	185
53	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. Blood, 2014, 124, 3841-3849.	1.4	185
54	High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood, 2012, 120, 4783-4794.	1.4	179

#	Article	IF	Citations
55	Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and V3-21 Usage Characterize Discordance of ZAP-70 and VH Mutation Status in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2006, 24, 969-975.	1.6	177
56	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2019, 37, 1391-1402.	1.6	177
57	Molecular Imaging of Proliferation in Malignant Lymphoma. Cancer Research, 2006, 66, 11055-11061.	0.9	173
58	Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood, 2006, 107, 2889-2894.	1.4	167
59	Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood, 2010, 115, 4497-4506.	1.4	167
60	Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood, 2004, 104, 2600-2602.	1.4	157
61	Allogeneic Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia With 17p Deletion: A Retrospective European Group for Blood and Marrow Transplantation Analysis. Journal of Clinical Oncology, 2008, 26, 5094-5100.	1.6	157
62	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet, The, 2019, 394, 2271-2281.	13.7	155
63	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood, 2019, 134, 111-122.	1.4	145
64	Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica, 2019, 104, e434-e437.	3.5	144
65	Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. Journal of Clinical Oncology, 2016, 34, 3758-3765.	1.6	142
66	First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.. Blood, 2009, 114, 535-535.	1.4	142
67	Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene, 1998, 16, 1891-1897.	5.9	139
68	t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. , 2000, 27, 285-294.		137
69	Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network. Journal of Clinical Oncology, 2014, 32, 1338-1346.	1.6	137
70	VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood, 2003, 102, 3003-3009.	1.4	136
71	Evolution of DNA Methylation Is Linked to Genetic Aberrations in Chronic Lymphocytic Leukemia. Cancer Discovery, 2014, 4, 348-361.	9.4	135
72	Epigenetic Upregulation of lncRNAs at 13q14.3 in Leukemia Is Linked to the In Cis Downregulation of a Gene Cluster That Targets NF-kB. PLoS Genetics, 2013, 9, e1003373.	3.5	134

#	Article	IF	Citations
73	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematology,the, 2016, 3, e388-e397.	4.6	128
74	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2018, 24, 4371-4379.	7.0	127
75	Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood, 2002, 99, 4554-4561.	1.4	125
76	Exclusive Detection of the t(11;18)(q21;q21) in Extranodal Marginal Zone B Cell Lymphomas (MZBL) of MALT Type in Contrast to other MZBL and Extranodal Large B Cell Lymphomas. American Journal of Pathology, 1999, 155, 1817-1821.	3.8	124
77	Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood, 2008, 111, 2246-2252.	1.4	122
78	Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood, 2011, 117, 6450-6458.	1.4	121
79	Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2012, 30, 2483-2491.	1.6	120
80	Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood, 2003, 101, 2049-2053.	1.4	116
81	Molecular Characterization of 11q Deletions Points to a Pathogenic Role of the ATM Gene in Mantle Cell Lymphoma. Blood, 1999, 94, 3262-3264.	1.4	114
82	Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia. Hematology American Society of Hematology Education Program, 2010, 2010, 481-488.	2.5	112
83	Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood, 2016, 128, 395-404.	1.4	112
84	Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2012, 30, 2211-2217.	1.6	110
85	Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood, 2017, 129, 2702-2705.	1.4	108
86	Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood, 2012, 119, 4101-4107.	1.4	107
87	CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. International Journal of Cancer, 2001, 91, 474-480.	5.1	106
88	Human NACHT, LRR, and PYD domainâ€"containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. Journal of Allergy and Clinical Immunology, 2017, 140, 1054-1067.e10.	2.9	105
89	The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood, 2004, 103, 2850-2858.	1.4	101
90	Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica, 2014, 99, 1095-1100.	3.5	101

#	Article	IF	Citations
91	Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nature Communications, 2019, 10, 1459.	12.8	99
92	Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 2008, 112, 325-325.	1.4	99
93	TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood, 2013, 121, 3284-3288.	1.4	96
94	Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. OncoImmunology, 2016, 5, e1150399.	4.6	94
95	TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica, 2018, 103, 1956-1968.	3.5	94
96	Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2018, 19, 1215-1228.	10.7	94
97	188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. British Journal of Haematology, 2005, 130, 604-613.	2.5	92
98	Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. Blood, 2002, 99, 4116-4121.	1.4	91
99	A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood, 2011, 118, 4159-4168.	1.4	91
100	MINCR is a MYC-induced lncRNA able to modulate MYCâ€™s transcriptional network in Burkitt lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5261-70.	7.1	91
101	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 2117-2125.	2.0	87
102	Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. Leukemia and Lymphoma, 2016, 57, 789-796.	1.3	87
103	Genetic Imbalances in Progressed B-Cell Chronic Lymphocytic Leukemia and Transformed Large-Cell Lymphoma (Richter's Syndrome). American Journal of Pathology, 2002, 161, 957-968.	3.8	86
104	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood, 2020, 135, 1859-1869.	1.4	86
105	High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. Blood, 2018, 132, 892-902.	1.4	83
106	Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood, 2020, 135, 2402-2412.	1.4	83
107	B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions. Human Molecular Genetics, 2001, 10, 1275-1285.	2.9	81
108	Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes and Cancer, 2007, 46, 494-499.	2.8	81

#	Article	IF	Citations
109	Poor efficacy and tolerability of <scp>Râ€CHOP</scp> in relapsed/refractory chronic lymphocytic leukemia and <scp>R</scp>ichter transformation. American Journal of Hematology, 2014, 89, E239-43.	4.1	81
110	Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. Haematologica, 2011, 96, 408-416.	3.5	80
111	Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. Genes Chromosomes and Cancer, 2001, 31, 316-325.	2.8	75
112	Importance of genetics in chronic lymphocytic leukemia. Blood Reviews, 2011, 25, 131-137.	5.7	75
113	Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Journal of Clinical Oncology, 2021, 39, 4049-4060.	1.6	74
114	Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway. Cell Cycle, 2008, 7, 3810-3814.	2.6	72
115	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood, 2021, 137, 1365-1376.	1.4	72
116	TP53 mutation and survival in aggressive B cell lymphoma. International Journal of Cancer, 2017, 141, 1381-1388.	5.1	69
117	First Demonstration of Leukemia Imaging with the Proliferation Marker ¹⁸F-Fluorodeoxythymidine. Journal of Nuclear Medicine, 2008, 49, 1756-1762.	5.0	68
118	NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood, 2013, 122, 1266-1270.	1.4	68
119	Risk Stratification in Chronic Lymphocytic Leukemia. Seminars in Oncology, 2006, 33, 186-194.	2.2	67
120	Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in highâ€risk Bâ€cell chronic lymphocytic leukemia. International Journal of Cancer, 2007, 121, 1984-1993.	5.1	67
121	Evidence for Distinct Pathomechanisms in Genetic Subgroups of Chronic Lymphocytic Leukemia Revealed by Quantitative Expression Analysis of Cell Cycle, Activation, and Apoptosis-Associated Genes. Journal of Clinical Oncology, 2005, 23, 3780-3792.	1.6	66
122	Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood, 2017, 130, 1477-1480.	1.4	63
123	Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood, 2014, 124, 19-19.	1.4	62
124	Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. Best Practice and Research in Clinical Haematology, 2007, 20, 439-453.	1.7	61
125	Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIGÂ®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors. Blood, 2014, 124, 330-330.	1.4	61
126	Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood, 2010, 116, 4223-4230.	1.4	60

#	Article	IF	Citations
127	Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ TÂcell population that sustains anti-tumor immunity. Immunity, 2021, 54, 2825-2841.e10.	14.3	57
128	Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 417-423.	1.3	56
129	Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in Tâ€cell prolymphocytic leukemia. Cancer, 2013, 119, 2258-2267.	4.1	56
130	Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 4527-4533.	7.0	56
131	FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. Blood, 2019, 133, 830-839.	1.4	56
132	A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia. Cancer Research, 2009, 69, 8977-8986.	0.9	55
133	Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. British Journal of Haematology, 2010, 148, 948-950.	2.5	55
134	Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Practice and Research in Clinical Haematology, 2010, 23, 71-84.	1.7	55
135	From Biology to Therapy: The CLL Success Story. HemaSphere, 2019, 3, e175.	2.7	55
136	Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues. Leukemia, 2019, 33, 625-637.	7.2	55
137	IGLV3-21 * 01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4320-4327.	7.1	55
138	Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood, 2006, 107, 2090-2093.	1.4	54
139	Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7741-7746.	7.1	54
140	Quantitative Gene Expression Deregulation in Mantle-Cell Lymphoma: Correlation With Clinical and Biologic Factors. Journal of Clinical Oncology, 2007, 25, 2770-2777.	1.6	54
141	Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG). Blood, 2008, 112, 330-330.	1.4	54
142	Epigenetic silencing of miR-708 enhances NF-ÎºB signaling in chronic lymphocytic leukemia. International Journal of Cancer, 2015, 137, 1352-1361.	5.1	52
143	CD5⁺ B cells from individuals with systemic lupus erythematosus express granzyme B. European Journal of Immunology, 2010, 40, 2060-2069.	2.9	51
144	Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. British Journal of Haematology, 2018, 180, 666-679.	2.5	51

#	Article	IF	Citations
145	IGF1R as druggable target mediating PI3K-Î´ inhibitor resistance in a murine model of chronic lymphocytic leukemia. Blood, 2019, 134, 534-547.	1.4	51
146	PI3KÎ´ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. Leukemia, 2019, 33, 1427-1438.	7.2	51
147	IG-MYC+ neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas. Blood, 2018, 132, 2280-2285.	1.4	50
148	Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody. Oncology Research and Treatment, 2015, 38, 185-192.	1.2	49
149	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 2022, 36, 1870-1878.	7.2	47
150	Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leukemia Research, 2015, 39, 495-500.	0.8	46
151	BRAFmutations in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1177-1182.	1.3	45
152	Prognostic and Predictive Factors in Patients With Chronic Lymphocytic Leukemia: Relevant in the Era of Novel Treatment Approaches?. Journal of Clinical Oncology, 2014, 32, 869-872.	1.6	45
153	Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology,the, 2017, 4, e475-e486.	4.6	45
154	Expression of Costimulatory Molecules in Low-Grade Mucosa-Associated Lymphoid Tissue-Type Lymphomas in Vivo. American Journal of Pathology, 1999, 155, 2019-2027.	3.8	44
155	The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. International Journal of Cancer, 2013, 133, 1489-1496.	5.1	44
156	Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab. Frontiers in Oncology, 2020, 10, 1578.	2.8	44
157	Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica, 2020, 105, 2598-2607.	3.5	44
158	Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. International Journal of Cancer, 2006, 118, 1831-1835.	5.1	43
159	Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis. Haematologica, 2016, 101, 1380-1389.	3.5	43
160	Chronic lymphocytic leukemia and 13q14: miRs and more. Leukemia and Lymphoma, 2009, 50, 502-505.	1.3	42
161	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica, 2015, 100, 511-516.	3.5	42
162	Telomere dysfunction and chromothripsis. International Journal of Cancer, 2016, 138, 2905-2914.	5.1	42

#	Article	IF	Citations
163	The Phospholipase CÎ³2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein. Journal of Biological Chemistry, 2016, 291, 22136-22148.	3.4	42
164	Discovery of Candidate DNA Methylation Cancer Driver Genes. Cancer Discovery, 2021, 11, 2266-2281.	9.4	42
165	Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. Blood, 2003, 101, 699-702.	1.4	41
166	Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations. Haematologica, 2008, 93, 680-687.	3.5	41
167	Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment. Blood, 2013, 121, 2503-2511.	1.4	41
168	17p Deletion Predicts for Inferior Overall Survival after Fludarabine - Based First Line Therapy in Chronic Lymphocytic Leukemia: First Analysis of Genetics in the CLL4 Trial of the GCLLSG.. Blood, 2005, 106, 715-715.	1.4	41
169	Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model. Acta Neuropathologica Communications, 2016, 4, 87.	5.2	40
170	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia, 2021, 35, 3059-3072.	7.2	40
171	Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG). Blood, 2013, 122, 526-526.	1.4	40
172	The CLL12 trial: ibrutinib vs placebo in treatment-naÃ¯ve, early-stage chronic lymphocytic leukemia. Blood, 2022, 139, 177-187.	1.4	40
173	Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis. British Journal of Haematology, 2008, 142, 538-550.	2.5	39
174	Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nature Communications, 2017, 8, 153.	12.8	39
175	Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks. Molecular Systems Biology, 2019, 15, e8339.	7.2	39
176	COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia, 2020, 34, 2225-2229.	7.2	39
177	Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma. British Journal of Haematology, 2003, 122, 193-201.	2.5	38
178	CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia, 2019, 33, 1161-1172.	7.2	38
179	Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia, 2020, 34, 2038-2050.	7.2	38
180	Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG).. Blood, 2009, 114, 205-205.	1.4	38

#	Article	IF	Citations
181	Molecular diagnostics in chronic lymphocytic leukemia â€“ Pathogenetic and clinical implications. Leukemia and Lymphoma, 2008, 49, 864-873.	1.3	37
182	Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. Blood, 2011, 117, 1817-1821.	1.4	37
183	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticÂleukaemia treated with ibrutinib from 3 clinical trials. British Journal of Haematology, 2018, 182, 504-512.	2.5	37
184	Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. Haematologica, 2020, 105, 170-181.	3.5	37
185	Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells. Blood, 2013, 121, 4708-4717.	1.4	36
186	A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. Blood, 2021, 138, 71-71.	1.4	36
187	Treatment resistance in chronic lymphocytic leukemiaâ€“the role of the p53 pathway. Leukemia and Lymphoma, 2009, 50, 510-513.	1.3	35
188	DNA damageâ€“induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Blood, 2011, 117, 1622-1632.	1.4	35
189	Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 715-722.e6.	0.4	35
190	Translocation t(X;11)(q13;q23) in Bâ€cell chronic lymphocytic leukemia disrupts two novel genes. Genes Chromosomes and Cancer, 2005, 42, 128-143.	2.8	34
191	The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica, 2008, 93, 1111-1113.	3.5	34
192	The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncology, 2015, 11, 1895-1903.	2.4	34
193	Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). Haematologica, 2015, 100, 1451-1459.	3.5	34
194	Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas. Leukemia, 2021, 35, 2002-2016.	7.2	34
195	NFATC1 activation by <scp>DNA</scp> hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. International Journal of Cancer, 2018, 142, 322-333.	5.1	33
196	Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATEâ„¢-17 Trial. Blood, 2014, 124, 327-327.	1.4	33
197	Nurseâ€like cells show deregulated expression of genes involved in immunocompetence. British Journal of Haematology, 2011, 154, 349-356.	2.5	32
198	Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood, 2019, 133, 494-497.	1.4	32

#	Article	IF	Citations
199	Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia â€“ First Results Of a Randomized German-French Cooperative Phase III Trial. Blood, 2013, 122, 524-524.	1.4	32
200	Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. Haematologica, 2010, 95, 102-109.	3.5	31
201	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clinical Cancer Research, 2020, 26, 2096-2103.	7.0	31
202	Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. Haematologica, 2020, 105, 2440-2447.	3.5	31
203	Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial. Blood, 2008, 112, 328-328.	1.4	31
204	High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood, 2020, 135, 866-870.	1.4	30
205	Subcutaneous Campath-1H (Alemtuzumab) in Fludarabine-Refractory Cll: Interim Analysis of the CLL2h Study of the German Cll Study Group (GCLLSG).. Blood, 2004, 104, 478-478.	1.4	30
206	Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood, 2022, 139, 1318-1329.	1.4	30
207	Prognostic markers and standard management of chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 2015, 2015, 368-377.	2.5	29
208	Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Cell Death and Disease, 2019, 10, 571.	6.3	29
209	Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. Haematologica, 2017, 102, 968-971.	3.5	28
210	Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. Leukemia, 2018, 32, 1778-1786.	7.2	28
211	Chronic Lymphocytic Leukemia-Derived Extracellular Vesicles Contain a Distinctive Proteome, As Well As Specific Micro RNAs and Y RNAs. Blood, 2014, 124, 1968-1968.	1.4	28
212	Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. Blood, 2012, 119, 4851-4859.	1.4	27
213	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. Clinical Cancer Research, 2017, 23, 5292-5301.	7.0	27
214	CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncology, 2018, 14, 499-513.	2.4	27
215	EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia. Leukemia, 2021, 35, 2311-2324.	7.2	27
216	Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematology,the, 2021, 8, e648-e657.	4.6	27

#	Article	IF	Citations
217	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL) Tj ETQq1 1 0.784314 rgBT /Ove	1.4	27
218	Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group. Leukemia and Lymphoma, 2013, 54, 1821-1822.	1.3	26
219	Progranulin Is a Novel Independent Predictor of Disease Progression and Overall Survival in Chronic Lymphocytic Leukemia. PLoS ONE, 2013, 8, e72107.	2.5	26
220	Kruppel-like factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of NOTCH signaling. Haematologica, 2016, 101, e249-e253.	3.5	26
221	Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin. Haematologica, 2018, 103, 688-697.	3.5	26
222	Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. Lancet Oncology, The, 2019, 20, 1576-1586.	10.7	26
223	Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice. Haematologica, 2021, 106, 968-977.	3.5	26
224	EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia. Leukemia, 2021, 35, 3152-3162.	7.2	26
225	Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment. Blood, 2016, 128, 2770-2770.	1.4	26
226	Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes. Haematologica, 2008, 93, 1912-1916.	3.5	25
227	Highâ€throughput detection of nuclear factorâ€kappaB activity using a sensitive oligoâ€based chemiluminescent enzymeâ€linked immunosorbent assay. International Journal of Cancer, 2010, 127, 404-411.	5.1	25
228	Front-line treatment of CLL in the era of novel agents. Cancer Treatment Reviews, 2017, 53, 70-78.	7.7	25
229	Venetoclax: Targeting BCL2 in Hematological Cancers. Recent Results in Cancer Research, 2018, 212, 215-242.	1.8	25
230	Molecular Cytogenetic Analysis of RB-1 Deletions in Chronic B-Cell Leukemias. Leukemia and Lymphoma, 1994, 16, 97-103.	1.3	24
231	Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia. European Journal of Haematology, 2011, 87, 426-433.	2.2	24
232	Germline Allele-Specific Expression of DAPK1 in Chronic Lymphocytic Leukemia. PLoS ONE, 2013, 8, e55261.	2.5	24
233	Management of Chronic Lymphocytic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 164-175.	3.8	24
234	Cryptic insertion of MYC exons 2 and 3 into the immunoglobulin heavy chain locus detected by whole genome sequencing in a case of â€œMYC-negativeâ€•Burkitt lymphoma. Haematologica, 2020, 105, e202-e205.	3.5	24

#	Article	IF	Citations
235	Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. Haematologica, 2020, 105, 1379-1390.	3.5	24
236	Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group. Leukemia, 2020, 34, 1038-1051.	7.2	24
237	The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. Leukemia, 2020, 34, 296-300.	7.2	23
238	Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. Leukemia, 2020, 34, 115-127.	7.2	23
239	Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Expert Opinion on Pharmacotherapy, 2020, 21, 917-929.	1.8	23
240	Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm. Current Oncology Reports, 2020, 22, 16.	4.0	22
241	Antagonizing inactivated tumor suppressor genes and activated oncogenes by a versatile transgenesis system: application in mantle cell lymphoma. FASEB Journal, 2006, 20, 1188-1190.	0.5	21
242	FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3550-3559.	6.4	21
243	Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial. Blood, 2013, 122, 6-6.	1.4	21
244	CDKN2 gene deletion is not found in chronic lymphoid leukaemias of B- and T-cell origin but is frequent in acute lymphoblastic leukaemia. British Journal of Haematology, 1995, 91, 865-870.	2.5	20
245	Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia. Leukemia, 2019, 33, 2531-2535.	7.2	20
246	The involvement of microRNA in the pathogenesis of Richter syndrome. Haematologica, 2019, 104, 1004-1015.	3.5	20
247	Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1575-1580.	2.0	20
248	Noncatalytic Bruton's tyrosine kinase activates PLCÎ³2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells. Journal of Biological Chemistry, 2020, 295, 5717-5736.	3.4	20
249	Current Treatment Options in CLL. Cancers, 2021, 13, 2468.	3.7	20
250	Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, Progression-Free Survival, Delayed Neutropenias and Secondary Malignancies Confirm Superiority of the FCR Regimen. Blood, 2012, 120, 435-435.	1.4	20
251	Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial.. Journal of Clinical Oncology, 2013, 31, 7004-7004.	1.6	20
252	Treating chronic lymphocytic leukemia with thalidomide and lenalidomide. Expert Opinion on Pharmacotherapy, 2011, 12, 2857-2864.	1.8	19

#	Article	IF	Citations
253	Telomere length in mantle cell lymphoma. Blood, 2013, 121, 1184-1187.	1.4	19
254	Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. European Journal of Haematology, 2016, 97, 253-260.	2.2	19
255	Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. Haematologica, 2018, 103, 1889-1898.	3.5	19
256	MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma. Cancer Research, 2019, 79, 3125-3138.	0.9	19
257	Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. Leukemia, 2019, 33, 2183-2194.	7.2	19
258	Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial. Blood, 2008, 112, 781-781.	1.4	19
259	Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial.. Blood, 2009, 114, 207-207.	1.4	19
260	Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group. Blood, 2016, 128, 3227-3227.	1.4	19
261	Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2013, 31, 7014-7014.	1.6	19
262	Molecular genetics and its clinical relevance. Hematology/Oncology Clinics of North America, 2004, 18, 827-848.	2.2	18
263	How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/orTP53mutation?. Leukemia and Lymphoma, 2015, 56, 587-593.	1.3	18
264	Stromal cell protein kinase C-Î² inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance. Science Translational Medicine, 2020, 12, .	12.4	18
265	Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial. Blood, 2019, 134, 36-36.	1.4	18
266	Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) - Comprehensive Analysis of the CLL4 Trial of the GCLLSG.. Blood, 2008, 112, 2089-2089.	1.4	18
267	Refractory chronic lymphocytic leukemia - new therapeutic strategies. Oncotarget, 2010, 1, 472-482.	1.8	18
268	Targeting inhibitor of apoptosis proteins by <scp>S</scp>mac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia. International Journal of Cancer, 2015, 137, 2959-2970.	5.1	17
269	Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*. Leukemia and Lymphoma, 2016, 57, 1291-1299.	1.3	17
270	Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg. Blood, 2012, 120, 302-302.	1.4	17

#	Article	IF	Citations
271	Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions. Blood, 2015, 126, 496-496.	1.4	17
272	Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. Blood, 2016, 128, 4393-4393.	1.4	17
273	Mutation analysis of the TNFAIP3 (A20) tumor suppressor gene in CLL. International Journal of Cancer, 2011, 128, 1747-1750.	5.1	16
274	Reconstruction of rearranged Tâ€cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of Tâ€cell prolymphocytic leukemia. Genes Chromosomes and Cancer, 2020, 59, 261-267.	2.8	16
275	Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation). Blood, 2018, 132, 694-694.	1.4	16
276	Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine â€“ Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW. Blood, 2010, 116, 920-920.	1.4	16
277	Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation. Journal of Nuclear Medicine, 2006, 47, 278-86.	5.0	16
278	BCMSUN, a candidate gene for B-cell chronic lymphocytic leukemia and mantle-cell lymphoma, has an independently expressed homolog on 1p22-p31,BCMSUN-like. International Journal of Cancer, 2000, 88, 692-697.	5.1	15
279	Overview of available p53 function tests in relation toTP53andATMgene alterations and chemoresistance in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1849-1853.	1.3	15
280	Extracellular vesicles in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1826-1830.	1.3	15
281	Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica, 2015, 100, e311-4.	3.5	15
282	New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabineâ€“mitoxantroneâ€“cyclophosphamideâ€“alemtuzumab induction followed by alemtuzumab maintenance. Leukemia and Lymphoma, 2019, 60, 649-657.	1.3	15
283	Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL. Genome Medicine, 2020, 12, 29.	8.2	15
284	Adjuvant Therapy of High-Risk (Stages IICâ€“IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 637161.	2.8	15
285	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. Nature Communications, 2021, 12, 5395.	12.8	15
286	Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma. Blood, 2014, 124, 3067-3067.	1.4	15
287	Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study. Blood, 2015, 126, 833-833.	1.4	15
288	The Use of Chemoimmunotherapy Improves the Outcome of Patients with Chronic Lymphocytic Leukaemia (CLL) â€“ a Metaanalysis of Five Trials of the German CLL Study Group (GCLLSG). Blood, 2012, 120, 3936-3936.	1.4	15

#	Article	IF	Citations
289	Fatal Ophiostoma piceae infection in a patient with acute lymphoblastic leukaemia. Journal of Medical Microbiology, 2009, 58, 381-385.	1.8	14
290	PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. Blood, 2014, 124, 420-425.	1.4	14
291	MARCKS affects cell motility and response to BTK inhibitors in CLL. Blood, 2021, 138, 544-556.	1.4	14
292	Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA. Blood, 2018, 132, 781-781.	1.4	14
293	Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 3345-3345.	1.4	14
294	Functional characterization of phospholipase C-Î³2 mutant protein causing both somatic ibrutinib resistance and a germline monogenic autoinflammatory disorder. Oncotarget, 2018, 9, 34357-34378.	1.8	14
295	Reciprocal translocation t(12;13)(p13;q14) in acute nonlymphoblastic leukemia: Report and cytogenetic analysis of two cases. Cancer Genetics and Cytogenetics, 1994, 77, 106-110.	1.0	13
296	17p Deletion in Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America, 2013, 27, 289-301.	2.2	13
297	Prospective Evaluation of Prognostic Parameters in Early Stage Chronic Lymphocytic Leukemia (CLL): Results of the CLL1-Protocol of the German CLL Study Group (GCLLSG).. Blood, 2007, 110, 625-625.	1.4	13
298	Quantitative MRD Assessments Predict Progression Free Survival in CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab â€“ a Prospective Analysis in 471 Patients from the Randomized GCLLSG CLL8 Trial. Blood, 2008, 112, 326-326.	1.4	13
299	Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. Blood, 2014, 124, 4453-4453.	1.4	13
300	Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial. Blood, 2016, 128, 511-511.	1.4	13
301	Advances in treating chronic lymphocytic leukemia. F1000prime Reports, 2014, 6, 65.	5.9	13
302	High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia. International Journal of Cancer, 2007, 121, 978-983.	5.1	12
303	Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse. British Journal of Haematology, 2007, 136, 127-130.	2.5	12
304	BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2009, 50, 1837-1842.	1.3	12
305	SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL). British Journal of Haematology, 2010, 150, 633-636.	2.5	12
306	Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. Leukemia and Lymphoma, 2018, 59, 1614-1623.	1.3	12

#	Article	IF	Citations
307	Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. Haematologica, 2021, 106, 859-862.	3.5	12
308	Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial. Haematologica, 2021, 106, 543-554.	3.5	12
309	Telomere Dysfunction in Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2020, 10, 612665.	2.8	12
310	Prognostic Impact and Risk Factors of Reducing Prescribed Doses of Fludarabine, Cyclophosphamide and Rituximab (FCR) during Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 4156-4156.	1.4	12
311	Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study. Blood, 2015, 126, 493-493.	1.4	12
312	Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group). Blood, 2016, 128, 229-229.	1.4	12
313	Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood, 2016, 128, 3230-3230.	1.4	12
314	Refractory chronic lymphocytic leukemia--new therapeutic strategies. Oncotarget, 2010, 1, 472-82.	1.8	12
315	Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia. Haematologica, 2010, 95, 1441-1443.	3.5	11
316	Ofatumumab Combined With Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Results From a Randomized, Multicenter, International, Two-Dose, Parallel-Group Phase II Trial. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, E33-E34.	0.4	11
317	Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6. International Journal of Cancer, 2015, 136, 65-73.	5.1	11
318	TBETâ€expressing Th1 CD4⁺T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in EÂµâ€TCL1 mice. British Journal of Haematology, 2020, 189, 133-145.	2.5	11
319	Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma. Haematologica, 2021, 106, 2224-2232.	3.5	11
320	Role of Specific B-Cell Receptor Antigens in Lymphomagenesis. Frontiers in Oncology, 2020, 10, 604685.	2.8	11
321	Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy. Haematologica, 2022, 107, 604-614.	3.5	11
322	Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).. Blood, 2007, 110, 3106-3106.	1.4	11
323	Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG).. Blood, 2007, 110, 3120-3120.	1.4	11
324	Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG. Blood, 2010, 116, 2427-2427.	1.4	11

#	Article	IF	Citations
325	Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in â€œultra High-riskâ€•CLL: Final Results from the CLL2O Phase II Study. Blood, 2014, 124, 1991-1991.	1.4	11
326	Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia. Blood, 2016, 128, 192-192.	1.4	11
327	Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood, 2016, 128, 4382-4382.	1.4	11
328	Chronic Lymphocytic Leukemia: New Concepts for Future Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, 369-378.	0.4	10
329	Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement. British Journal of Haematology, 2019, 186, e203-e207.	2.5	10
330	Elevated Hedgehog activity contributes to attenuated DNA damage responses in aged hematopoietic cells. Leukemia, 2020, 34, 1125-1134.	7.2	10
331	Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study. Haematologica, 2021, 106, 682-691.	3.5	10
332	Increased Bâ€•cell activity with consumption of activated monocytes in severe COVIDâ€•19 patients. European Journal of Immunology, 2021, 51, 1449-1460.	2.9	10
333	B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood, 2021, 137, 2267-2271.	1.4	10
334	Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.4	10
335	Anti-Leukemia Activity of the Selective BCL-2 Inhibitor ABT-199 in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By MCL-1/BCL-2 Expression Serving As Biomarker for Treatment Response. Blood, 2016, 128, 1081-1081.	1.4	10
336	Activation of Notch and Myc Signaling via B-cellâ€“Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. Cancer Research, 2021, 81, 6117-6130.	0.9	10
337	Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. European Journal of Haematology, 2017, 98, 254-262.	2.2	9
338	BIRC3 mutations in chronic lymphocytic leukemia â€“ uncommon and unfavorable. Haematologica, 2020, 105, 255-256.	3.5	9
339	LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome. Blood, 2021, 137, 3251-3258.	1.4	9
340	TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.. Blood, 2009, 114, 1267-1267.	1.4	9
341	Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL. Blood, 2010, 116, 58-58.	1.4	9
342	Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. Blood, 2010, 116, 921-921.	1.4	9

#	Article	IF	Citations
343	NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911). Blood, 2013, 122, 527-527.	1.4	9
344	11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. Blood, 2016, 128, 2042-2042.	1.4	9
345	Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11 Study Population. Blood, 2016, 128, 4401-4401.	1.4	9
346	CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial. Blood, 2016, 128, 640-640.	1.4	9
347	Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations. Blood, 2022, 139, 3340-3344.	1.4	9
348	Pathogenic complexity of gastric B-cell lymphoma. Blood, 2002, 100, 1095-1097.	1.4	8
349	The gene expression signature associated with <scp>TP</scp>53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the underâ€expression of <scp>TP</scp>53 and other genes on chromosome 17p. British Journal of Haematology, 2013, 160, 53-62.	2.5	8
350	Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia. OncoTargets and Therapy, 2017, Volume 10, 645-656.	2.0	8
351	Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. Leukemia, 2020, 34, 441-450.	7.2	8
352	Early Autologous Stem Cell Transplantation (SCT) in Genetically Poor-Risk Chronic Lymphocytic Leukemia Is Feasible and Effective: Results from a Prospective Multicenter Study (GCLLSG CLL3) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 37	1.4	8
353	CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial. Blood, 2015, 126, 4151-4151.	1.4	8
354	Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). Blood, 2016, 128, 2054-2054.	1.4	8
355	In Chronic Lymphocytic Leukemia Î”CT7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation. Blood, 2016, 128, 971-971.	1.4	8
356	Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy. American Journal of Hematology, 2022, 97, .	4.1	8
357	Genetics, Gene Expression, and Targeted Therapies in Chronic Lymphocytic Leukemia. Current Drug Targets, 2006, 7, 1313-1327.	2.1	7
358	Genetics of Chronic Lymphocytic Leukemia. Clinics in Laboratory Medicine, 2011, 31, 649-658.	1.4	7
359	CLL and deletion 13q14: merely the miRs?. Blood, 2012, 119, 2974-2975.	1.4	7
360	Assessment of <scp>TP</scp>53 functionality in chronic lymphocytic leukaemia by different assays; an <scp>ERIC</scp>â€wide approach. British Journal of Haematology, 2014, 167, 565-569.	2.5	7

#	Article	IF	Citations
361	Outcome of patients aged 80Âyears or older treated for chronic lymphocytic leukaemia. British Journal of Haematology, 2018, 183, 727-735.	2.5	7
362	Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization. American Journal of Hematology, 2021, 96, E311-E314.	4.1	7
363	Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations. Blood, 2021, 138, 1805-1816.	1.4	7
364	Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial). Blood, 2019, 134, 1754-1754.	1.4	7
365	Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab (FC-Cam) in Patients with Relapsed or Genetic High-Risk CLL: Final Analysis of the CLL2L Trial of the German CLL Study Group.. Blood, 2009, 114, 209-209.	1.4	7
366	Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.. Blood, 2009, 114, 3433-3433.	1.4	7
367	Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial. Blood, 2012, 120, 433-433.	1.4	7
368	Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW. Blood, 2012, 120, 716-716.	1.4	7
369	Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study. Blood, 2014, 124, 3327-3327.	1.4	7
370	In Vivo modeling of Resistance to PI3KÎ´ Inhibitor Treatment Using EÂµTCL1-Tg Tumor Transfer Model. Blood, 2016, 128, 190-190.	1.4	7
371	Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. Blood, 2016, 128, 4395-4395.	1.4	7
372	The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2018, 36, TPS7582-TPS7582.	1.6	7
373	17p Deletion in CLL: Detailed Analysis of TP53 Mutations, Alternative Mechanisms of p53 Inactivation, Clone Size and Clonal Evolution. Blood, 2008, 112, 782-782.	1.4	7
374	Danish CLL2â€Study revisited: FISH on a cohort with a 20â€yr followâ€up confirms the validity of the hierarchical model of genomic aberrations in chronic lymphocytic leukaemia. European Journal of Haematology, 2009, 83, 156-158.	2.2	6
375	Chronic lymphocytic leukemia - genomics lead the way. Haematologica, 2011, 96, 1402-1405.	3.5	6
376	Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia. Blood, 2017, 130, 2443-2444.	1.4	6
377	Antiâ€<scp>CD</scp>20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the <scp>CLLX</scp>4 trial. British Journal of Haematology, 2019, 184, 833-836.	2.5	6
378	Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. Leukemia, 2020, 34, 1177-1181.	7.2	6

#	Article	IF	Citations
379	DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy. Scientific Data, 2020, 7, 133.	5.3	6
380	Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. British Journal of Haematology, 2021, 193, 325-338.	2.5	6
381	Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. Leukemia and Lymphoma, 2021, 62, 3440-3451.	1.3	6
382	Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study). Blood, 2008, 112, 565-565.	1.4	6
383	Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroupsâ€“ Results From the CLL8 Trial of the German CLL Study Group (GCLLSG). Blood, 2011, 118, 1777-1777.	1.4	6
384	Role Of High-Dose Cytarabine and Total Body Irradiation Conditioning before Autologous Stem Cell Transplantation In Mantle Cell Lymphoma - A Comparison Of Nordic MCL2, HOVON 45, and European MCL Younger Trials. Blood, 2013, 122, 3367-3367.	1.4	6
385	Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3337-3337.	1.4	6
386	Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study. Blood, 2015, 126, 2934-2934.	1.4	6
387	Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199,) Tj ETQq1 1 0.784314 rgBT /Ov Chronic Lymphocytic Leukemia. Blood, 2015, 126, 829-829.	1.4	6
388	A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.. Journal of Clinical Oncology, 2018, 36, TPS7588-TPS7588.	1.6	6
389	Strikingly Homologous Immunoglobulin Gene Rearrangements and Poor Outcome in VH3-21-Utilizing Chronic Lymphocytic Leukemia Independent of Geographical Origin and Mutational Status.. Blood, 2005, 106, 175-175.	1.4	6
390	NFATc1 Is Transcriptionally Activated in Chronic Lymphocytic Leukemia (CLL) By Promotor DNA-Hypomethylation Which Correlates with in-Vitro Vulnerability to Calcineurin Inhibitors. Blood, 2014, 124, 1941-1941.	1.4	6
391	Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. HemaSphere, 2022, 6, e692.	2.7	6
392	Duplication of chromosome arms 9q and 11q: Evidence for a novel, 14q32 translocationâ€“independent pathogenetic pathway in multiple myeloma. Genes Chromosomes and Cancer, 2005, 42, 78-81.	2.8	5
393	Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk. Haematologica, 2010, 95, 1880-1888.	3.5	5
394	Immunoglobulin Heavy Chain Variable Gene Usage and (Super)-antigen Drive in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2010, 16, 373-375.	7.0	5
395	TCL1A and ATM are co-expressed in chronic lymphocytic leukemia cells without deletion of 11q. Haematologica, 2013, 98, 269-273.	3.5	5
396	Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia. Oncology Research and Treatment, 2016, 39, 34-40.	1.2	5

#	Article	IF	Citations
397	Ibrutinib-resistant CLL: unwanted and unwonted!. Blood, 2017, 129, 1407-1409.	1.4	5
398	Dissecting the Prognostic Significance and Functional Role of Progranulin in Chronic Lymphocytic Leukemia. Cancers, 2019, 11, 822.	3.7	5
399	Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). American Journal of Hematology, 2019, 94, 1002-1006.	4.1	5
400	U-RT1 â€“ A new model for Richter transformation. Neoplasia, 2021, 23, 140-148.	5.3	5
401	Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019. Intensive Care Medicine Experimental, 2021, 9, 45.	1.9	5
402	Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 3134-3134.	1.4	5
403	Hypophosphatemia after High Dosage Iron Substitution with Ferric Carboxymaltose (FCM) and Iron Isomaltoside (IM) â€” the Randomised Controlled Home Afers 1 Trial. Blood, 2018, 132, 3627-3627.	1.4	5
404	A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood, 2019, 134, 4297-4297.	1.4	5
405	Minimal Residual Disease (MRD) Kinetics after Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) Correlate to IgH VH Mutational Status and Predict Post Transplant Outcome: Real Time ASO-IgH PCR Results of the GCLLSG CLL3 Protocol.. Blood, 2004, 104, 147-147.	1.4	5
406	Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: A Retrospective EBMT Analysis.. Blood, 2007, 110, 47-47.	1.4	5
407	Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 2104-2104.	1.4	5
408	Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG). Blood, 2013, 122, 4127-4127.	1.4	5
409	Molecular and Immunological Effects of Thalidomide in Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 2092-2092.	1.4	5
410	KIR2DS1â€“HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Lancet Haematology,the, 2022, 9, e133-e142.	4.6	5
411	Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy. Bone Marrow Transplantation, 2021, 56, 195-201.	2.4	4
412	Four-Factor Score for Outcome of Ibrutinib Treatment in Chronic Lymphocytic Leukemia: Prognostic Model for Risk Group Definition. Journal of Clinical Oncology, 2021, 39, 551-553.	1.6	4
413	Consolidation with Alemtuzumab in First Remission Induces Pronounced MRD Reduction and Clinical Remissions - Update on a Randomized Phase III Trial of the German CLL Study Group (GCLLSG).. Blood, 2004, 104, 2506-2506.	1.4	4
414	Fludarabine Versus Fludarabine Plus Epirubicin in the Treatment of Chronic Lymphocytic Leukemia - Final Results of a German Randomized Phase-III Study.. Blood, 2005, 106, 2123-2123.	1.4	4

#	Article	IF	Citations
415	Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers. Blood, 2008, 112, 329-329.	1.4	4
416	Subclonal Driver Mutations Predict Shorter Progression Free Survival in Chronic Lymphocytic Leukemia Following First-Line Chemo(immuno)Therapy: Results from the CLL8 Trial. Blood, 2014, 124, 1938-1938.	1.4	4
417	Gene Mutations and Treatment Outcome in CLL Patients Treated with Chlorambucil (Chl) or Ofatumumab-Chl (O-Chl): Results from the Phase III Study COMPLEMENT1 (OMB110911). Blood, 2014, 124, 1992-1992.	1.4	4
418	Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG). Blood, 2014, 124, 23-23.	1.4	4
419	Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy. Blood, 2015, 126, 362-362.	1.4	4
420	Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG). Blood, 2016, 128, 2044-2044.	1.4	4
421	Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL. Blood, 2016, 128, 231-231.	1.4	4
422	Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial.. Journal of Clinical Oncology, 2019, 37, 7523-7523.	1.6	4
423	Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial.. Journal of Clinical Oncology, 2020, 38, 8027-8027.	1.6	4
424	Correlation of Quantitative Gene Expression by RQ-PCR with Clinical and Biologic Factors in Mantle Cell Lymphoma.. Blood, 2004, 104, 696-696.	1.4	4
425	In Vitro Activity of the Type II Anti-CD20 Antibody GA101 in Refractory, Genetic High-Risk CLL.. Blood, 2009, 114, 2379-2379.	1.4	4
426	Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survival. Leukemia and Lymphoma, 2009, 50, 1559-1561.	1.3	3
427	MDM2 promotor polymorphism and disease characteristics in CLL. Leukemia Research, 2010, 34, 578-579.	0.8	3
428	Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia. Therapeutic Advances in Hematology, 2011, 2, 249-265.	2.5	3
429	Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leukemia and Lymphoma, 2017, 58, 348-356.	1.3	3
430	Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma. Frontiers in Oncology, 2020, 10, 580364.	2.8	3
431	Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study. Bone Marrow Transplantation, 2021, 56, 692-695.	2.4	3
432	Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients. Leukemia, 2021, , .	7.2	3

#	Article	IF	Citations
433	Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up. Blood, 2019, 134, 3308-3308.	1.4	3
434	A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood, 2019, 134, 3047-3047.	1.4	3
435	p53 Inactivation in CLL: Pattern of 110 TP53 Mutations.. Blood, 2007, 110, 2064-2064.	1.4	3
436	Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab in Patients with Relapsed/Refractory CLL: Interim Analysis of the CLL2L Trial of the German CLL Study Group. Blood, 2008, 112, 3170-3170.	1.4	3
437	Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial. Blood, 2010, 116, 2357-2357.	1.4	3
438	TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study). Blood, 2013, 122, 1638-1638.	1.4	3
439	Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial. Blood, 2013, 122, 671-671.	1.4	3
440	Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial. Blood, 2016, 128, 682-682.	1.4	3
441	Targeted therapy in CLL: changing the treatment paradigm. Oncotarget, 2019, 10, 4002-4003.	1.8	3
442	Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial. Leukemia and Lymphoma, 2022, 63, 326-334.	1.3	3
443	IgG seroprevalence of COVIDâ€19 among people living with HIV or at high risk of HIV in southâ€west Germany: A seroprevalence study. HIV Medicine, 2021, , .	2.2	3
444	High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial. Blood, 2021, 138, 72-72.	1.4	3
445	Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440). Haematologica, 2021, 106, 2834-2844.	3.5	3
446	Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. HemaSphere, 2022, 6, e729.	2.7	3
447	**102 Chemoimmunotherapy with Ofatumumab, Fludarabine and Cyclophosphamide (O-FC) in Previously Untreated Patients with Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S119-S120.	0.4	2
448	4.13 Proposal of a New Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on an Overall Survival Analysis of Three German CLL Study Group Phase III Trials. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S225-S227.	0.4	2
449	MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. Haematologica, 2014, 99, 1285-1291.	3.5	2
450	Impact of telomere length on the outcome of allogeneic stem cell transplantation for poorâ€risk chronic lymphocytic leukaemia: results from the <scp>GCLLSG CLL</scp>3X trial. British Journal of Haematology, 2017, 179, 342-346.	2.5	2

#	Article	IF	Citations
451	Rapid detection of ATM/p53 function with p27Kip FACS analysis: a novel diagnostic tool for chronic lympocytic leukemia?. Leukemia and Lymphoma, 2017, 58, 6-7.	1.3	2
452	Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential. Cancer Immunology, Immunotherapy, 2020, 69, 1535-1548.	4.2	2
453	Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. Haematologica, 2021, , .	3.5	2
454	Identification of Posttranvslationally Modified Neoantigens As Targets of B Cell Receptors of Burkitt Lymphoma. Blood, 2018, 132, 1588-1588.	1.4	2
455	Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study. Blood, 2018, 132, 1856-1856.	1.4	2
456	Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy. Blood, 2018, 132, 4433-4433.	1.4	2
457	The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study. Blood, 2018, 132, 3140-3140.	1.4	2
458	Role of FDG PET/CT to Detect Bone Marrow Involvement in the Initial Staging of Aggressive Non-Hodgkin Lymphoma. Blood, 2019, 134, 2892-2892.	1.4	2
459	ZAP-70 Expression, VH-Mutation Status, Genomic Aberrations and Prognosis in Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 1920-1920.	1.4	2
460	Thalidomide Alone and in Combination with Fludarabine Exerts Distinct Molecular and Antileukemic Effects in B-Cell Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 3124-3124.	1.4	2
461	Identification of Genes Associated with Resistance and Response in Vivo to Therapy with Rituximab, Fludarabine and Cyclophosphamide in Patients with Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 1622-1622.	1.4	2
462	Peptide Vaccination Induces Dynamic Changes in CD4+ and CD8+ T Cell Subsets: Report on the First Peptide Vaccination Trial in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2008, 112, 3159-3159.	1.4	2
463	Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.. Blood, 2009, 114, 879-879.	1.4	2
464	Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG). Blood, 2010, 116, 918-918.	1.4	2
465	Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy. Blood, 2011, 118, 1793-1793.	1.4	2
466	Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW. Blood, 2011, 118, 2854-2854.	1.4	2
467	Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study). Blood, 2011, 118, 2859-2859.	1.4	2
468	Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group. Blood, 2011, 118, 2860-2860.	1.4	2

#	Article	IF	Citations
469	Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide,) Tj ETQq1 1 0.784314 rgBT /Overlock	1.4	2
470	A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study. Blood, 2013, 122, 1645-1645.	1.4	2
471	Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG). Blood, 2014, 124, 4699-4699.	1.4	2
472	Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study).. Journal of Clinical Oncology, 2018, 36, 12048-12048.	1.6	2
473	Inherited DNA repair and cell cycle gene defects in chronic lymphocytic leukemia.. Journal of Clinical Oncology, 2019, 37, 1508-1508.	1.6	2
474	Differential Diagnosis, Staging and Prognostic Factors. , 2008, , 103-119.		2
475	Quantitative Gene Expression Analysis of Surrogate Markers for Genetic Risk Groups and Survival in CLL. Blood, 2008, 112, 4170-4170.	1.4	2
476	Identification and Characterization of Peptide Ligands for Stereotyped Subset and Non-Subset B-Cell Receptors of Patients with M- and U-CLL.. Blood, 2009, 114, 4369-4369.	1.4	2
477	Response: Or both?. Blood, 2008, 111, 5756-5757.	1.4	1
478	More (on) prognostic factors in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2010, 51, 5-6.	1.3	1
479	Immune modulatory agents in hematopoietic malignancies. Cancer Treatment Reviews, 2011, 37, S2-S7.	7.7	1
480	P53 and microRNAs in chronic lymphocytic leukemia. Journal of Nucleic Acids Investigation, 2011, 2, 8.	0.8	1
481	Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chÅ‚oniakiem z komÃ³rek pÅ‚aszcza â€“ wyniki miÄ™dzynarodowego, wielooÅ›rodkowego, badania II fazy z ibrutynibem (PCI-32765) â€“ EHA Encore. Acta Haematologica Polonica, 2013, 44, 314-318.	0.3	1
482	Chronic Lymphocytic Leukemia With TP53 Aberrations: Breakthroughs and Challenges. Journal of Oncology Practice, 2017, 13, 381-382.	2.5	1
483	Effect of Dose Modifications on Response to Duvelisib in Patients with Relapsed/Refractory (R/R) CLL/SLL in the DUO Trial. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S273-S274.	0.4	1
484	Response to Comment by Jonathan Weiss et al.. Haematologica, 2019, 104, e542-e542.	3.5	1
485	No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. Leukemia and Lymphoma, 2021, 62, 837-845.	1.3	1
486	Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 4430-4430.	1.4	1

#	Article	IF	Citations
487	NOTCH1 Signaling Is Activated in CLL By Mutations of FBXW7 and Low Expression of USP28 at 11q23. Blood, 2018, 132, 946-946.	1.4	1
488	Vecabrutinib Is Efficacious In Vivo in a Preclinical CLL Adoptive Transfer Model. Blood, 2018, 132, 1868-1868.	1.4	1
489	Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440). Blood, 2018, 132, 1859-1859.	1.4	1
490	Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy. Blood, 2019, 134, 3035-3035.	1.4	1
491	Comparison of Overall Survival in High Risk Patients with Minimal Residual Disease after First-Line Treatment across Three Generations of Phase 3 Trials of the German CLL Study Group. Blood, 2019, 134, 3040-3040.	1.4	1
492	In-Vitro Treatment of Chronic Lymphocytic Leukemia (CLL) Cells with Fludarabine, Etoposide and Alemtuzumab (Campath-1H) Reveals Different Rates and Mechanisms of Cell Death.. Blood, 2005, 106, 2112-2112.	1.4	1
493	Graft Versus Host Disease-Like Syndrome after Autologous Stem Cell Transplantation in CLL Patients Treated with a TBI/Cy/Alemtuzumab (CAMPATH-1H) High-Dose Regimen.. Blood, 2005, 106, 2928-2928.	1.4	1
494	Clonal Evolution in Chronic Lymphocytic Leukemia: Acquisition of High-Risk Genomic Aberrations Associated with Unmutated VH, Resistance to Therapy, and Short Survival.. Blood, 2006, 108, 296-296.	1.4	1
495	Standardized MRD Flow and ASO IGH RQ-PCR for MRD Quantification in CLL Patients after Rituximab-Containing Immunochemotherapy â€“ a Comparative Analysis in 574 Samples from the Randomized GCLLSG CLL8 Trial. Blood, 2008, 112, 3139-3139.	1.4	1
496	Induction of Apoptosis in CLL by Peptides Binding the B-Cell Antigen Receptor in Vitro. Blood, 2008, 112, 3151-3151.	1.4	1
497	Effective Targeting of the PI3-K Pathway in CLL with NVP-BEZ235, a Novel Orally Available Dual PI3K/mTOR Inhibitor. Blood, 2008, 112, 3166-3166.	1.4	1
498	Identification of RHAMM-Derived CD8+ Restricted, Heteroclitical, Cryptic Epitope R9Y as a Promising Target for Immunotherapy of Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 3034-3034.	1.4	1
499	Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). Blood, 2010, 116, 1376-1376.	1.4	1
500	High-Resolution SNP-Array Profiling of Chronic Lymphocytic Leukemia. Blood, 2010, 116, 50-50.	1.4	1
501	MicroRNA-130a Targets ATG2B, AGO4 and DICER1, Inhibits Autophagy and Induces Cell Death in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 1768-1768.	1.4	1
502	Assessment of p53 Functionality in Chronic Lymphocytic Leukemia by Different Assays; An Eric-Wide Approach.. Blood, 2012, 120, 2872-2872.	1.4	1
503	SF3B1, NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial. Blood, 2012, 120, 966-966.	1.4	1
504	Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 2436-2436.	1.4	1

#	Article	IF	Citations
505	Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity. Blood, 2015, 126, 821-821.	1.4	1
506	Targeting Mutant p53 in Pediatric Acute Lymphoblastic Leukemia. Blood, 2015, 126, 903-903.	1.4	1
507	CLL Exosome-Derived Y RNA hY4 Induces TLR7/8-Mediated Inflammation and PD-L1 Expression in Monocytes. Blood, 2016, 128, 3217-3217.	1.4	1
508	Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. Blood, 2016, 128, 4376-4376.	1.4	1
509	A comprehensive prognostic index for patients with CLL.. Journal of Clinical Oncology, 2013, 31, 7015-7015.	1.6	1
510	The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study.. Journal of Clinical Oncology, 2018, 36, 7533-7533.	1.6	1
511	MRD Kinetics Can Predict the Time to Relapse after Autologous Stem Cell Transplantation (SCT) in Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 714-714.	1.4	1
512	Mir-34a as Part of the Chemotherapy Resistance Network in Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 1209-1209.	1.4	1
513	In-Vitro Treatment with the AKT-Inhibitor GSK 690693 Induces Cell Death in Lymphoma Cell Lines and in Primary CLL Cells and Is Followed by Caspase-3 Activation and Cytochrome C Release.. Blood, 2008, 112, 1589-1589.	1.4	1
514	TP53 Abnormalities in Chronic Lymphocytic Leukemia Exhibit a Disease Specific Profile: Meta-Analysis of 270 Mutations.. Blood, 2008, 112, 2077-2077.	1.4	1
515	Neuropilin-1 â€“ Novel, Promising Target for Chronic Lymphocytic Leukemia patients.. Blood, 2009, 114, 4392-4392.	1.4	1
516	Exceptional In Vitro Activity of CD37 Antibodies In CLL. Blood, 2010, 116, 2460-2460.	1.4	1
517	SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). Blood, 2011, 118, 263-263.	1.4	1
518	ADARB1 Is Involved In a Reduced Maturation Of The miR15a/Mir-16-1 Family In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 1252-1252.	1.4	1
519	Prognostic Assessment In Patients With Chronic Lymphocytic Leukemia (CLL) In Clinical Practice: A European Research Initiative On CLL (ERIC) Survey. Blood, 2013, 122, 4156-4156.	1.4	1
520	Genomic Mechanisms of 17p / TP53 Loss in Primary â€œultra High-riskâ€•and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. Blood, 2014, 124, 2184-2184.	1.4	1
521	Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG). Blood, 2016, 128, 4394-4394.	1.4	1
522	Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL.. Journal of Clinical Oncology, 2018, 36, 7526-7526.	1.6	1

#	Article	IF	Citations
523	BAR-Bodies: B-Cell Receptor Antigens As the Targeting Moiety of Antibodies in Substitution for the Variable Region of Heavy and Light Chains. Blood, 2018, 132, 2940-2940.	1.4	1
524	Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRDâ€“) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.. Journal of Clinical Oncology, 2019, 37, 7502-7502.	1.6	1
525	Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2. Blood, 2019, 134, 1507-1507.	1.4	1
526	Pooled Analysis of First-Line Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Aged 80 Years and Older. Blood, 2021, 138, 1552-1552.	1.4	1
527	Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial. Blood, 2021, 138, 2639-2639.	1.4	1
528	Advances in the use of alemtuzumab in CLL. Clinical Advances in Hematology and Oncology, 2008, 6, 23-4.	0.3	1
529	Tâ€cell prolymphocytic leukemia is associated with deregulation of oncogenic <scp>microRNAs</scp> on transcriptional and epigenetic level. Genes Chromosomes and Cancer, 2022, 61, 432-436.	2.8	1
530	The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia. Leukemia, 2022, 36, 1794-1805.	7.2	1
531	Update on Genomic Profiling in Chronic Lymphocytic Leukemia. Clinical Leukemia, 2007, 1, 217-222.	0.2	0
532	4.19 Prediction of Poor Outcome in Chronic Lymphocytic Leukemia Patients treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S230.	0.4	0
533	4.23 MDM2 Promotor Polymorphism and Disease Characteristics in CLL: Individual Patient Data Meta-Analysis of 2598 CLL Patients. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S233-S235.	0.4	0
534	Missing the notch in NOTCH1. Leukemia and Lymphoma, 2013, 54, 1579-1580.	1.3	0
535	An Improved Benefit-Risk Profile of Duvelisib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received â‰¥2 Prior Therapies. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S276.	0.4	0
536	Poster: CLL-115: First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S220.	0.4	0
537	Protein Expression Patterns of Candidate Genes Involved in Apoptosis and Cell Cycle Control in Genetic Subgroups of Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 2796-2796.	1.4	0
538	Prognostic Relevance of Lipoprotein Lipase (LPL) Expression in B-CLL.. Blood, 2004, 104, 177-177.	1.4	0
539	Differential Expression Patterns of Apoptotis and Cell Cycle Proteins after Staurosporine Treatment in EHEB (B-CLL) and JURKAT (T-ALL) Cell Lines.. Blood, 2004, 104, 4304-4304.	1.4	0
540	High ZAP-70 and Differential Expression of B-Cell Receptor Related Genes in Chronic Lymphocytic Leukemia with V3-21 Gene Usage.. Blood, 2004, 104, 773-773.	1.4	0

#	Article	IF	Citations
541	Protein Expression Analysis of Chromosome 12 Candidate Genes in Chronic Lymphocytic Leukemia (B-CLL).. Blood, 2004, 104, 4797-4797.	1.4	0
542	The Paternally Expressed Gene 10 (PEG10) on Chromosome 7q21 Is Overexpressed and Imprinted in High-Risk B-CLL.. Blood, 2005, 106, 1221-1221.	1.4	0
543	Short Telomeres Are Associated with Genetic Instability and the Occurrence of High Risk Genomic Aberrations in Chronic Lymphocytic Leukemia.. Blood, 2005, 106, 1178-1178.	1.4	0
544	Occurrence of Chromosomal Translocations as Independent Prognostic Factor in Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2084-2084.	1.4	0
545	RHAMM/CD168 Is a Novel Leukemia Associated Antigen with Prognostic Value for Patients with B-Cell Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2773-2773.	1.4	0
546	Influence of MDM2 Single Nucleotide Polymorphism SNP309 on Disease Onset and Course in CLL.. Blood, 2006, 108, 4938-4938.	1.4	0
547	Array-CGH Based Genomic Profiling in B-Cell Chronic Lymphocytic Leukemia Reveals Specific Correlations of Genomic Imbalances and Prognostic Subgroups and Underlines the Consistency of Chromosomal Aberration Patterns within This Disease.. Blood, 2006, 108, 2083-2083.	1.4	0
548	Prognostic Assessment of Three Single Nucleotide Polymorphisms (BCL2â€“938C>A, MTHFR) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.4	0
549	Gene Expression Signature of B-Cell Chronic Lymphocytic Leukemia with Trisomy 12.. Blood, 2007, 110, 2079-2079.	1.4	0
550	In-Vitro Treatment of Lymphoma Cell Lines with BAY 43-9006 (Sorafenib) Is Followed by Typical Features of Apoptosis and Down-Regulation of MCL-1 Pointing to an Efficacy of Sorafenib in the Teatment of Lymphoma.. Blood, 2007, 110, 1392-1392.	1.4	0
551	The Receptor for Hyaluronic Acid Mediated Motility (RHAMM): Characterization as an Immunotherapeutical Target in Chronic Lymphocytic Leukemia (CLL) and First Results of RHAMM-Derived Peptide Vaccination Trial.. Blood, 2007, 110, 2051-2051.	1.4	0
552	BCRs of Mutated and Unmutated CLL Bind Peptides with Distinct Sequence Features: Evidence from Phage Display Libraries.. Blood, 2007, 110, 1118-1118.	1.4	0
553	Uncovering the Epigenetic Pathomechanism in 13q14.. Blood, 2007, 110, 487-487.	1.4	0
554	Autoimmune or Chronic Infectious Disease in B-CLL at Diagnosis: Association with Unmutated VH Gene Status and Unfavorable Cytogenetics.. Blood, 2007, 110, 3092-3092.	1.4	0
555	The Response to DNA Damage in CLL Cells Is Partly Determined by the Type of TP53 Mutation and Genomic Aberrations. Blood, 2008, 112, 3119-3119.	1.4	0
556	Epimutation of the Tumor Suppressor Mechanism in 13q14.3 Involves Monoallelic Expression, Non-Coding RNA Genes and Deregulation of NFkB Signalling. Blood, 2008, 112, 783-783.	1.4	0
557	Comprehensive Protein Expression Analysis of Chronic Lymphocytic Leukemia Uncovers a Correlation of CDK4, P27 and P53 with Hierarchical Risk and Suggests a Dichotomy of Apoptosis and Proliferation.. Blood, 2009, 114, 1255-1255.	1.4	0
558	A Novel Paradigm to Trigger Apoptosis in Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 731-731.	1.4	0

#	Article	IF	Citations
559	Detection of NFÎºB Activity in Primary CLL Cells Using a Sensitive Oligo-Based Chemiluminescent ELISA.. Blood, 2009, 114, 4709-4709.	1.4	0
560	In-Vitro Effect of the Small Molecule Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Chronic Lymphocytic Leukemia (CLL).. Blood, 2009, 114, 4408-4408.	1.4	0
561	IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG). Blood, 2010, 116, 3609-3609.	1.4	0
562	Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study. Blood, 2010, 116, 2184-2184.	1.4	0
563	Maturation of the miR15a/miR16-1 Family Is Impaired In Chronic Lymphocytic Leukaemia. Blood, 2010, 116, 53-53.	1.4	0
564	Uncovering Thalidomide Mechanism of Action: Neuropilin 1 Represents the Target of Antiangiogenic and Immunomodulatory Effect in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 4608-4608.	1.4	0
565	The Toll-Like Receptor-Like Molecule CD180 and Soluble CD14 Transmit Survival Signals in B-Cell Chronic Lymphocytic Leukemia Cells Presumably by Acting As Co-Receptors,. Blood, 2011, 118, 3883-3883.	1.4	0
566	Prognostic Impact of Biallelic Versus Monoallelic Deletion 13q and the Proportion of Cells with Deletion 13q within the CLL8 Trial of the German CLL Study Group (GCLLSG). Blood, 2011, 118, 2841-2841.	1.4	0
567	Reduced c-FOS Is Associated with Poor Prognosis and Clinical Course in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 2433-2433.	1.4	0
568	Role of Microenvironment-Associated Chemokines and Cytokines for Binet Stage A CLL Patients Included in a Prospective Trial (CLL1 trial) of the German CLL Study Group (GCLLSG): sIl2Ralpha Is An Independent Predictor of Progression-Free Survival (PFS),. Blood, 2011, 118, 3869-3869.	1.4	0
569	Proposal of A Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on An Overall Survival Analysis of Three German CLL Study Group Phase III Trials. Blood, 2011, 118, 2831-2831.	1.4	0
570	Lenalidomide Reduces Survival of Chronic Lymphocytic Leukemia Cells in Primary Co-Cultures by Altering the Myeloid Microenvironment. Blood, 2012, 120, 3894-3894.	1.4	0
571	Autoantigenic Targets of B-Cell Receptors (BCR) Derived From Chronic Lymphocytic Leukemias Bind to and Induce Proliferation of Leukemic Cells.. Blood, 2012, 120, 2884-2884.	1.4	0
572	TP53 Mutation Is an Independent Predictor of Poor Survival in Untreated Patients with CD20+ Aggressive B-Cell Lymphoma: Analysis within the Ricover-60 Trial. Blood, 2012, 120, 546-546.	1.4	0
573	Telomere Length in Mantle Cell Lymphoma.. Blood, 2012, 120, 2509-2509.	1.4	0
574	IL4 and CD40L Prevent Apoptosis of Chronic Lymphocytic Leukemia Cells Via Intracellular pSTAT6 and NFkB Signaling and Not Via Receptor Kinetics. Blood, 2012, 120, 3893-3893.	1.4	0
575	Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.. Blood, 2012, 120, 2874-2874.	1.4	0
576	MicroRNAs in Hematologic Malignancies. , 2014, , 67-95.		0

#	Article	IF	Citations
577	Novel Gene Mutations In Chronic Lymphocytic Leukemia: Prevalence and Clinical Implications In A Series Of 3185 Cases - Initial Results From The European Research Initiative On CLL. Blood, 2013, 122, 1614-1614.	1.4	0
578	Microenvironmental Factors and The Role Of Tumor Necrosis Factor Receptor Type 1 (TNFR-1) In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 4149-4149.	1.4	0
579	Heterogeneity and Evolution Of DNA Methylation In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 1626-1626.	1.4	0
580	Identification of the Antigenic Targets of the Major CLL-Derived Stereotyped BCRs and First Demonstration of Sub-Subsets. Blood, 2014, 124, 298-298.	1.4	0
581	Charting Unique Signatures of Somatic Hypermutation Amongst Chronic Lymphocytic Leukemia Patients Expressing IGHV4-34 Clonotypic B Cell Receptors. Blood, 2014, 124, 1969-1969.	1.4	0
582	Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial. Blood, 2014, 124, 1951-1951.	1.4	0
583	High-Resolution Genomic Copy Number Analysis on Sequential Samples from the CLL8 Trial: Relation Between Clonal Evolution and Defects in DNA Damage Response?. Blood, 2014, 124, 1964-1964.	1.4	0
584	High Dose-Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation for Patients with Refractory or Recurrent Primary Central Nervous System Lymphoma â€“Results of a Multicenter Study By the Germany Collaborative PCNSL Study Group. Blood, 2014, 124, 2527-2527.	1.4	0
585	Allogeneic HCT in Patients with 17p-CLL: Results of a Non-Interventional Study of the EBMT & Eric. Blood, 2014, 124, 1224-1224.	1.4	0
586	The Flavonoid Wogonin Reduces CLL Cell Survival in Vitro and Leukemia Development in EÂµ-TCL1 Mice By Targeting Aberrant TNF Receptor Signaling. Blood, 2014, 124, 1966-1966.	1.4	0
587	High Resolution Genomic Profiling of Primary â€œUltra High Riskâ€•and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. Blood, 2014, 124, 3288-3288.	1.4	0
588	Induction Treatment with Alemtuzumab Combined with Polychemotherapy Containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Followed By Alemtuzumab Maintenance in Patients with T-Cell Prolymphocytic Leukaemia (T-PLL): First Analysis of a Prospective Multicenter Phase-II-Trial (T-PLL2) Conducted By the German CLL Study Group (GCLLSG). Blood, 2014, 124, 1999-1999.	1.4	0
589	EÂµ-TCL1mTerc -/- Mouse Model for Telomere Dysfunction in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 1724-1724.	1.4	0
590	Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 365-365.	1.4	0
591	Microenvironmental Stromal Cells Rescue CLL Cells from Apoptosis Via Hypoxia That Can be Targeted Therapeutically. Blood, 2015, 126, 4140-4140.	1.4	0
592	CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. Blood, 2015, 126, 5263-5263.	1.4	0
593	Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL. Blood, 2015, 126, 1747-1747.	1.4	0
594	High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for Relapsed or Refractory Primary CNS Lymphoma - a Prospective Multicentre Trial By the German Cooperative PCNSL Study Group. Blood, 2016, 128, 781-781.	1.4	0

#	Article	IF	Citations
595	Assessment of Measures to Reduce Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab in the GREEN Study. Blood, 2016, 128, 5589-5589.	1.4	0
596	COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi)â€"A two-cohort phase II study.. Journal of Clinical Oncology, 2017, 35, TPS7567-TPS7567.	1.6	0
597	B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide.. Journal of Clinical Oncology, 2018, 36, 7531-7531.	1.6	0
598	Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia.. Journal of Clinical Oncology, 2018, 36, 7513-7513.	1.6	0
599	Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).. Journal of Clinical Oncology, 2018, 36, 7521-7521.	1.6	0
600	Gene Set Enrichment Analysis Suggests That Increased Rituximab-Mediated NK Cell Cytotoxicity after Vitamin D Substitution Is Driven By Upregulation of Interferon Alpha (IFN-a) Isoforms. Blood, 2018, 132, 3696-3696.	1.4	0
601	Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL. Blood, 2018, 132, 583-583.	1.4	0
602	Modeling of the Epigenome of the Cell-of-Origin Identifies Cancer-Specific DNA Methylation Patterns in CLL. Blood, 2018, 132, 3885-3885.	1.4	0
603	Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG). Blood, 2018, 132, 4429-4429.	1.4	0
604	MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy. Blood, 2018, 132, 1866-1866.	1.4	0
605	Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option. Blood, 2018, 132, 1580-1580.	1.4	0
606	CLL with Del (17p)/TP53 Mutation. Hematologic Malignancies, 2019, , 97-106.	0.2	0
607	Eomes and IL-10 Regulate Anti-Tumor Activity of T Cells in Chronic Lymphocytic Leukemia. Blood, 2019, 134, 4288-4288.	1.4	0
608	Modelling Single Cell B-Cell Receptor Signaling Reveals Enhanced Activity in Primary CLL Cells Compared to Non-Malignant Cells While Fundamental Network Circuit Topology Remains Stable Even with Novel Therapeutic Inhibitors. Blood, 2019, 134, 4275-4275.	1.4	0
609	The B-Cell Receptor Antigen ARS2 Can be Integrated into a BAR-Body Format to Treat Diffuse Large B-Cell Lymphomas in Xenograft Mouse Models. Blood, 2019, 134, 2860-2860.	1.4	0
610	Identification and Characterization of CMV-Specific, HLA-C*07:02 Restricted Antibodies. Blood, 2019, 134, 5616-5616.	1.4	0
611	Telomere Shortening By Terc Knockout in the EÂµ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival. Blood, 2019, 134, 1732-1732.	1.4	0
612	Characterization of Mechanisms of Acquired Venetoclax-Insensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2019, 134, 3954-3954.	1.4	0

#	Article	IF	Citations
613	Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood, 2021, 138, 3721-3721.	1.4	0
614	Robust Discovery of Candidate DNA Methylation Cancer Drivers. Blood, 2020, 136, 33-34.	1.4	0
615	ZAP-70 methylation and expression status in chronic lymphocytic leukemia. Haematologica, 2005, 90, 1012.	3.5	0
616	Chemoimmunotherapy in chronic lymphocytic leukemia. Clinical Advances in Hematology and Oncology, 2010, 8, 867-8.	0.3	0